Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Phase 1 Completed 61 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04937319 following multiple (14 days) escalating oral doses in patients with type 2 diabetes.

Timeline

Start: 2011-02
Primary completion: 2011-07
Completion: 2011-07

Publications

Sharma R, Litchfield J, Atkinson K, Eng H, Amin NB, Denney WS, Pettersen JC, Goosen TC, Di L, Lee E, Pfefferkorn JA, Dalvie DK, Kalgutkar AS. Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metab Dispos. 2014 Nov;42(11):1926-39. doi: 10.1124/dmd.114.060087. Epub 2014 Aug 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NERIGLIATIN	Small molecule	10 mg	Oral
Subject	NERIGLIATIN	Small molecule	30 mg	Oral
Subject	NERIGLIATIN	Small molecule	100 mg	Oral
Subject	NERIGLIATIN	Small molecule	300 mg	Oral

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications